Effects of rituximab injection: A Synthesis of Findings from 13 Studies

  1. Home
  2. Effects of rituximab injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of rituximab injection: A Synthesis of Findings from 13 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of rituximab injection: A Synthesis of Findings from 13 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Research on the effects of rituximab injection in HIV-infected individuals has yielded several key findings. 7 demonstrated the potential benefits of simplifying treatment regimens from tipranavir/ritonavir 500/200 twice daily to 500/100 twice daily, guided by therapeutic drug monitoring. While maintaining undetectable HIV-RNA levels, some patients experienced reductions in aminotransferases, total cholesterol, and even fasting triglycerides. 9 highlighted the potential of treatment simplification strategies, suggesting that induction with a ritonavir-boosted protease inhibitor regimen followed by simplification (without ritonavir) might offer sustained viral suppression while minimizing long-term adverse effects associated with ritonavir. 13 provided reassuring evidence that ritonavir-boosted protease inhibitor monotherapy did not increase the risk of neurocognitive impairment in stable HIV-positive patients compared to standard antiretroviral therapy. 1 showed that ritonavir can positively influence the immune system, leading to changes in T cell subset distribution and increases in CD4 and CD8 lymphocyte numbers and function. 8 demonstrated that ritonavir, in its commonly prescribed boosting dose, did not impact peripheral insulin sensitivity in healthy HIV-seronegative volunteers. 5 revealed that atazanavir combined with a lower dose of ritonavir had significantly less impact on glucose metabolism compared to lopinavir/ritonavir both in vitro and clinically. 6 highlighted the potential for lipid elevations associated with ritonavir-boosted protease inhibitors or efavirenz and nucleoside analogues, suggesting potential cardiovascular risk. 10 showed that LPV/r monotherapy might not be a reliable maintenance strategy, particularly for patients with a CD4 cell count nadir less than 200/microl. 3 studied the pharmacokinetics of ritonavir and its impact on rifabutin, revealing that ritonavir inhibited the metabolism of rifabutin and 25-O-desacetylrifabutin, suggesting that both are metabolized at least in part by CYP3A. 4 demonstrated that ritonavir can impair the clearance of trazodone and enhance its adverse effects, emphasizing the importance of considering potential drug interactions. 11 highlighted the favorable lipid effects and overall tolerability of ritonavir-boosted atazanavir and darunavir compared to ritonavir-boosted lopinavir. 12 provided evidence that darunavir with low-dose ritonavir and atazanavir with low-dose ritonavir showed comparable metabolic effects on insulin sensitivity over 48 weeks.

Benefits and Risks

Benefit Summary

Rituximab injection has demonstrated potential benefits in simplifying treatment regimens for HIV-infected individuals, potentially leading to reduced side effects and improved tolerability. 7 Additionally, ritonavir-boosted protease inhibitor monotherapy has been shown to have no adverse effects on neurocognitive function or brain imaging markers in stable HIV-positive patients. 13 Furthermore, ritonavir has been associated with positive effects on the immune system, leading to increases in CD4 and CD8 lymphocyte numbers and function. 1

Risk Summary

While offering potential benefits, rituximab injection carries certain risks, including the potential for reduced rituximab levels, impact on insulin sensitivity, lipid elevations, and drug interactions. 7 8 5 6 4 Moreover, rituximab monotherapy might not be suitable for all patients, particularly those with a low CD4 cell count nadir. 10

Research Comparisons

Research Similarities

Several research studies have highlighted the potential benefits of rituximab in managing HIV infection, with a common theme of improved treatment efficacy and tolerability. A significant focus has been on understanding the impact of ritonavir-boosted protease inhibitors on lipid metabolism. 7 9 13 6 11

Research Differences

Variability in research findings is likely due to differences in rituximab dosages, combinations with other medications, and patient characteristics. 7 9 13 1 8 5 6 10 3 4 11 12

Consistency and Contradictions

Research findings consistently suggest that rituximab injection can offer potential benefits for some patients, but also highlights the importance of carefully considering potential risks. 7 Rituximab monotherapy may not be appropriate for all individuals, particularly those with low CD4 cell counts. 10

Real-Life Applications and Precautions

When considering rituximab injection for HIV-infected individuals, it is crucial to carefully assess the dosage, combination with other medications, and individual patient characteristics. 7 10 Furthermore, the potential for drug interactions with other medications should be considered, and patients should consult with their healthcare providers to receive appropriate guidance. 4

Limitations of Current Research

Research on rituximab injection in HIV-infected individuals is still limited, particularly regarding long-term effects and safety. Further research is needed to gather more comprehensive data. 7 9 13 1 8 5 6 10 3 4 11 12

Future Research Directions

Further research is necessary to thoroughly evaluate the long-term effects and safety of rituximab injection, including optimal dosages and combinations with other medications. 7 9 13 1 8 5 6 10 3 4 11 12

Conclusion

While rituximab injection holds potential as a treatment option for some individuals with HIV, further research is essential to fully understand its efficacy and safety. 7 Patients should consult with their healthcare providers for personalized guidance and to ensure the appropriate use of rituximab, considering individual needs and potential risks. 7 9 13 1 8 5 6 10 3 4 11 12

Literature analysis of 13 papers
Positive Content
11
Neutral Content
0
Negative Content
2
Article Type
12
1
0
0
13
1.

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.

Author: KelleherA D, CarrA, ZaundersJ, CooperD A

HIV-1 infection treatment
Immune system improvement

Ritonavir, an HIV-1 protease inhibitor, significantly increased CD4 and CD8 lymphocyte counts and improved immune function in 21 patients.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.

Author: HsuA, GrannemanG R, WittG, LockeC, DenissenJ, MollaA, ValdesJ, SmithJ, ErdmanK, LyonsN, NiuP, DecourtJ P, FourtillanJ B, GiraultJ, LeonardJ M

Increased triglyceride levels

Ritonavir, an HIV treatment, showed moderately dose-dependent pharmacokinetics with concentration-dependent autoinduction. Triglyceride levels increased with higher ritonavir doses. This data provides information about its absorption, elimination, and potential side effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.

Author: CatoA, CavanaughJ, ShiH, HsuA, LeonardJ, GrannemanR

Increased rifabutin levels

Ritonavir significantly increases the plasma concentrations of rifabutin and its metabolite 25-O-desacetylrifabutin, suggesting that both drugs are metabolized by CYP3A.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.

Author: GreenblattDavid J, von MoltkeLisa L, HarmatzJerold S, FogelmanSteven M, ChenGengsheng, GrafJennifer A, MertzanisPolyxane, ByronSusan, CulmKerry E, GrandaBrian W, DailyJohanna P, ShaderRichard I

Drug interactions

Ritonavir significantly reduced apparent oral clearance of trazodone, prolonged elimination half-life, and increased peak plasma concentrations (mean +/- SE). Coadministration of trazodone with ritonavir increased sedation, fatigue, and performance impairment compared to trazodone plus placebo.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

6.

Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.

Author: HillAndrew, SawyerWill, GazzardBrian

Lipid elevation

There is a wide range of lipid elevations during 48 weeks of first-line HAART, depending on the choice of antiretrovirals used.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : English

7.

The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring.

Author: MorelloJudit, Rodríguez-NovoaSonia, BlancoFrancisco, VispoEugenia, BarreiroPablo, Gonzalez-PardoGema, Jiménez-NácherInmaculada, González-LahozJuan, SorianoVincent

HIV suppression
Reduced aminotransferases
Reduced cholesterol
Reduced triglycerides
Pill burden
Side effects

Tipranavir is a potent protease inhibitor but has a high pill burden and frequent side effects. This study found that reducing the ritonavir dose in patients taking tipranavir/ritonavir resulted in decreased liver enzymes and cholesterol levels in some patients without affecting viral suppression.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.

Author: TaylorSteven A, LeeGrace A, PaoVivian Y, AnthonypillaiJayaranjan, AweekaFrancesca T, SchwarzJean-Marc, MulliganKathleen, SchambelanMorris, GrunfeldCarl

Insulin resistance

Some HIV protease inhibitors (PIs), including full-dose ritonavir (800 mg) and ritonavir-boosted lopinavir, acutely induce insulin resistance in the absence of HIV infection. The effects of boosting dose ritonavir (100-200 mg) on glucose metabolism have not been described in the absence of another PI.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

9.

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

Author: SquiresKathleen E, YoungBenjamin, DejesusEdwin, BellosNicholaos, MurphyDaniel, ZhaoHenry H, PatelLisa G, RossLisa L, WannamakerPaul G, ShaeferMark S,

HIV treatment
Reduced side effects

Treatment simplification strategies involving induction with a ritonavir (RTV)-boosted protease inhibitor regimen followed by simplification without RTV may offer sustained virologic suppression while minimizing long-term adverse effects associated with RTV.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.

Author: GutmannChristine, CusiniAlexia, GünthardHuldrych F, FuxChristoph, HirschelBernard, DecosterdLaurent-Arthur, CavassiniMatthias, YerlySabine, VernazzaPietro L,

Reduced viral load
Treatment failure

Monotherapy with ritonavir-boosted lopinavir was not recommended as a standard strategy for HIV maintenance, especially in patients with a low nadir CD4 cell count. Viral failure was observed in patients with a low nadir CD4 cell count, and further research is needed to understand the role of the central nervous system in monotherapy failure.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.

Author: MartinezE, Gonzalez-CordonA, FerrerE, DomingoP, NegredoE, GutierrezF, PortillaJ, CurranA, PodzamczerD, MurillasJ, BernardinoJ I, SantosI, CartonJ A, PeraireJ, PichJ, PerezI, GatellJ M,

Lipid effects
Tolerability
Hyperbilirubinaemia

This study examines the lipid effects and overall tolerability of ritonavir-boosted atazanavir and darunavir compared to ritonavir-boosted lopinavir in patients with HIV infection.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.

Author: OvertonEdgar Turner, TebasPablo, CoateBruce, RyanRobert, PerniciaroAmy, DayaramYaswant K, De La RosaGuy, BaughBryan P

Darunavir with low-dose ritonavir (DRV/r) and atazanavir with low-dose ritonavir (ATV/r) are antiretroviral medications. This study assessed the effects of these agents on insulin sensitivity.

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.

Author: Arenas-PintoAlejandro, StöhrWolfgang, JägerHans Rolf, HaddowLewis, ClarkeAmanda, JohnsonMargaret, ChenFabian, WinstonAlan, GodiClaudia, ThustSteffi, TrombinRita, CairnsJanet, SolankyBhavana S, GolayXavier, PatonNicholas I,

HIV treatment

This study assessed the neurocognitive function and brain imaging markers of patients on ritonavir-boosted protease inhibitor (PI) monotherapy versus standard antiretroviral therapy (ART). There was no difference in neurocognitive impairment between the two groups. However, symptomatic neurocognitive impairment was associated with higher global cortical atrophy scores.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.